JP3496727B2 - Pharmaceutical base - Google Patents
Pharmaceutical baseInfo
- Publication number
- JP3496727B2 JP3496727B2 JP33288293A JP33288293A JP3496727B2 JP 3496727 B2 JP3496727 B2 JP 3496727B2 JP 33288293 A JP33288293 A JP 33288293A JP 33288293 A JP33288293 A JP 33288293A JP 3496727 B2 JP3496727 B2 JP 3496727B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- film
- dissolved
- spread
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【０００１】[0001]
【産業上の利用分野】本発明は新規な製剤用基剤に関す
るものである。詳しくは口腔用徐放製剤、直腸粘膜徐放
製剤、膣粘膜徐放製剤、創傷保護剤、可能性疾患用貼付
剤、徐放製錠剤等に好適に用いられる製剤用基剤に関す
る。FIELD OF THE INVENTION The present invention relates to a novel pharmaceutical base. More specifically, the present invention relates to a preparation base suitably used for sustained-release preparations for oral cavity, sustained-release preparations for rectal mucous membranes, sustained-release preparations for vaginal mucosa, wound protectants, patches for potential diseases, sustained-release tablets and the like.
【０００２】[0002]
【従来の技術】口腔用徐放製剤としては、支持層を用い
るか又は用いない口腔内粘膜貼付剤や、バッカル錠、舌
下錠、トローチ、チューアブル錠等があるが、一般的に
云って製法が繁雑であったり、徐放性が不充分とか再現
性がよくない、或いは徐放性のコントロールが困難など
の問題があった。そして支持層を用いる口腔内粘膜貼付
剤については支持層が薬物の透過を妨げるものでなけれ
ばならない場合が多く、そのためには腸溶性材料である
例えばエチルセルロースなどを用いるため、柔軟さが不
充分で異物感がおこり易いとか、凸部へ貼付した場合は
がれ易い等の問題があった。直腸粘膜徐放製剤として
は、坐剤や軟膏剤が知られているが、違和感があった
り、衣服がよごれる等の問題があった。膣粘膜徐放製剤
では、坐剤や貼付剤が知られているが、違和感や、はが
れ易い等の問題が、又創傷保護剤としては、絆創膏や
（包帯）があるが刺激があったり、柔軟性が不充分とい
う問題があった。化濃性疾患用貼付剤では刺激性や柔軟
性で問題があった。2. Description of the Related Art Oral sustained-release preparations include oral mucosal patches with or without a support layer, buccal tablets, sublingual tablets, troches, chewable tablets, etc. However, there were problems such as being complicated and having insufficient releasability or poor reproducibility, or being difficult to control the sustained release. And for the oral mucosa patch using a support layer, the support layer often has to be one that impedes drug permeation, and for that purpose, an enteric material such as ethyl cellulose is used, so that the flexibility is insufficient. There is a problem that a foreign substance is apt to occur, and that when it is attached to a convex portion, it easily peels off. Suppositories and ointments are known as rectal mucosa sustained-release preparations, but they have problems such as discomfort and stains on clothes. Suppositories and patches are known as vaginal mucosal sustained-release preparations, but they have problems such as discomfort and easy peeling. As wound-protecting agents, there are bandages and (bandages), which may cause irritation or softness. There was a problem of insufficient sex. The patch for concentrated diseases had problems with irritation and flexibility.
【０００３】[0003]
【発明が解決しようとする課題】従って、本発明の目的
は、徐放性について再現性がよく、またそのコントロー
ルも容易な、そして柔軟性に富むと共に弾力性、延伸性
のある製剤用基剤を提供することである。更には絆創膏
のガーゼ部や、化膿性疾患用貼付剤の皮膚接触部などの
材料として用いても違和感がなく、また坐剤や軟膏剤な
どに使用した場合でも衣服を汚すことがなく、刺激性の
少ない製剤用基剤を提供することである。SUMMARY OF THE INVENTION Therefore, the object of the present invention is to provide a sustained-release reproducible and easy-to-control, flexible, elastic, and stretchable base for preparations. Is to provide. Furthermore, it does not feel uncomfortable when used as a material for the gauze part of a plaster or the skin contact part of a patch for purulent diseases, and when used as a suppository or ointment, it does not stain clothes and is irritating. It is to provide a base material for a pharmaceutical product having a low content.
【０００４】[0004]
【課題を解決するための手段】本発明者等は上記目的に
鑑み鋭意研究を重ねた結果、ヒドロキシプロピルセルロ
ース（以下「ＨＰＣ」と記すこともある）及び／又はポ
リビニルピロリドン（以下「ＰＶＰ」と記すこともあ
る）とタンニン物質とをこれら物質可溶性の溶媒に溶解
した後溶媒を除去することによって得られる組成物が、
各種の徐放性製剤などの基剤としてすぐれた性質を具備
していることを知り、本発明を完成したものである。本
発明は（１）（ｉ）ヒドロキシプロピルセルロース、又
はヒドロキシプロピルセルロースとポリビニルピロリド
ンとの混合物、及び（ii）タンニン物質を、これら物質
可溶性の溶媒に溶解した後、得られる溶液から溶媒を除
去することによって得られるフィルムからなる製剤用基
剤、（２）タンニン物質がタンニン酸及び／又は没食子
酸である上記（１）記載の製剤用基剤、（３）ヒドロキ
シプロピルセルロースとタンニン酸とを組合せて用いる
上記（１）記載の製剤用基剤、（４）ヒドロキシプロピ
ルセルロース及びポリビニルピロリドンとタンニン酸と
を組合せて用いる上記（１）記載の製剤用基剤、（５）
（ｉ）ヒドロキシプロピルセルロース、又はヒドロキシ
プロピルセルロースとポリビニルピロリドンとの混合物
対（ii）タンニン物質の比が重量割合で１０００：１〜
５：１である上記（１）記載の製剤用基剤、（６）可塑
剤を含有してなる上記（１）記載の製剤用基剤、（７）
接着層を更に積層してなる上記（１）記載の製剤用基剤
に関するものである。Means for Solving the Problems As a result of intensive studies conducted by the present inventors in view of the above objects, hydroxypropyl cellulose (hereinafter sometimes referred to as “HPC”) and / or polyvinylpyrrolidone (hereinafter referred to as “PVP”) (Sometimes noted below) and a tannin substance are dissolved in a solvent in which these substances are soluble, and the composition obtained by removing the solvent is
The inventors have completed the present invention, knowing that it has excellent properties as a base for various sustained-release preparations. In the present invention, (1) (i) hydroxypropyl cellulose, or a mixture of hydroxypropyl cellulose and polyvinylpyrrolidone, and (ii) a tannin substance are dissolved in a solvent in which these substances are soluble, and then the solvent is removed from the resulting solution. A pharmaceutical base comprising a film thus obtained, (2) a pharmaceutical base according to the above (1), wherein the tannin substance is tannic acid and / or gallic acid, and (3) a combination of hydroxypropyl cellulose and tannic acid. (1) The pharmaceutical base according to (1) above, which is used in combination with (4) Hydroxypropylcellulose and polyvinylpyrrolidone, and the pharmaceutical base according to (1) above, which is used in combination with tannic acid.
The ratio of (i) hydroxypropyl cellulose or a mixture of hydroxypropyl cellulose and polyvinylpyrrolidone to (ii) the tannin material is 1000: 1 by weight.
The pharmaceutical base according to the above (1), which is 5: 1, (6) The pharmaceutical base according to the above (1), which comprises a plasticizer, (7)
The present invention relates to the pharmaceutical base according to (1) above, which further comprises an adhesive layer.
【０００５】本発明で用いられるＨＰＣは通常用いられ
る分子量１０，０００〜１，０００，０００の範囲のも
のを用いることができるが、分子量２０，０００〜１，
０００，０００のものが好ましく用いられる。そして特
に分子量１００，０００〜１，０００，０００のものが
好ましく用いられ、分子量２０，０００〜１００，００
０のものも本発明基剤の溶解性等のコントロールのため
に添加してもよい。本発明で用いられるＰＶＰは通常用
いられる分子量５，０００〜２，０００，０００の範囲
のものを用いることができるが、３０，０００〜２，０
００，０００の範囲のものを用いることが好ましい。本
発明で用いられるタンニン物質としては、タンニン酸、
没食子酸等が挙げられる。本発明において用いられる溶
媒は、各材料が溶解するものであれば特に制限はなく、
また各材料を均一に分散し得るものであるものも用いら
れるが、エタノール或いはエタノールと水の混合溶媒、
塩化メチレン等が好適に用いられる。本発明で得られる
製剤用基剤は、そのまま或いは可塑剤を配合して口腔内
粘膜貼付剤の支持層として好適に使用できるとともに、
坐剤の基剤、絆創膏のガーゼの代替品、化膿性疾患用貼
付剤の皮膚接触面部材等としても使用することができ
る。更には調製時、薬剤や可塑剤を配合することにより
非常に良好な各種の徐放性製剤（例えばトローチ、バツ
カル、口腔内粘膜貼付剤等の口腔用の徐放性製剤や一般
的徐放性錠剤等）を得ることができる。また本発明で得
られる製剤用基剤たる支持層の上に薬物含有接着層を通
常の方法で積層することによって口腔粘膜貼付剤とする
ことができ、この接着層としては本発明の製剤用基剤を
積層することもできる。本発明基剤において、所望によ
り使用する可塑剤としてはこの分野で通常用いられるも
のが用いられるが、プロピレングリコール、ブチレング
リコール、マクロゴール、ソルビトール、キシリトール
等の多価アルコールやヒマシ油、ペパーミント油、スペ
アミント油などの植物系油やタラ肝油や鯨油などの動物
系油、又流動パラフィンなどを挙げることができる。そ
の他の材料としてカルボキシビニルポリマーなども勿論
使用して差し支えない。更に着色料、矯味剤等も勿論使
用することができる。The HPC used in the present invention may have a commonly used molecular weight in the range of 10,000 to 1,000,000, but the molecular weight of 20,000 to 1,
Those of, 000,000 are preferably used. Particularly, those having a molecular weight of 100,000 to 1,000,000 are preferably used, and the molecular weight of 20,000 to 100,000.
No. 0 may be added to control the solubility of the base material of the present invention. The PVP used in the present invention may have a commonly used molecular weight in the range of 5,000 to 2,000,000, but 30,000 to 2,0.
It is preferable to use one having a range of 0,000. The tannin substance used in the present invention includes tannic acid,
Examples include gallic acid. The solvent used in the present invention is not particularly limited as long as each material can be dissolved,
Further, a material that can uniformly disperse each material is also used, but ethanol or a mixed solvent of ethanol and water,
Methylene chloride or the like is preferably used. The pharmaceutical base obtained in the present invention can be suitably used as it is or as a support layer of an oral mucosal patch by blending a plasticizer.
It can also be used as a base for suppositories, a substitute for gauze for adhesive plasters, a skin contact surface member for patches for purulent diseases, and the like. Furthermore, during preparation, it is possible to add various drugs and plasticizers at the time of preparation, and various very good sustained release preparations (eg lozenges, buccal, oral mucosal patches, etc. Tablets etc.) can be obtained. In addition, an oral mucosa patch can be prepared by laminating a drug-containing adhesive layer on a support layer, which is a base for preparations obtained by the present invention, by a conventional method. Agents can also be laminated. In the base of the present invention, as the plasticizer to be optionally used, those usually used in this field are used, but propylene glycol, butylene glycol, macrogol, sorbitol, polyhydric alcohols such as xylitol and castor oil, peppermint oil, Examples thereof include vegetable oils such as spearmint oil, animal oils such as cod liver oil and whale oil, and liquid paraffin. Of course, carboxyvinyl polymer or the like may be used as the other material. Further, coloring agents, flavoring agents and the like can of course be used.
【０００６】又本製剤用基剤に配合できる薬剤としては
特に制限はないが主なものを挙げれば下記のとおりであ
る。
解熱消炎鎮痛剤
インドメタシン、サリチル酸、アスピリン、アセトアミ
ノフエノン、ジクロフェナクナトリウム、イブプロフェ
ン
ステロイド系抗炎症剤
ヒドロコルチゾン、プレドニゾロン、フルオシノロンア
セトニド、酢酸ヒドロコルチゾン、酢酸ベタメタゾン、
トリアムシノロンアセトニド
高血圧、不整脈用剤
プロプラノロール、アテノロール、ピンドロール、硫酸
キニジン、塩酸アルプレノロール
抗腫瘍剤
５−フルオロウラシル、１−（２−テトラヒドロフリ
ル）−５−フルオロウラシル、マイトマイシンＣ
局所麻酔剤
ベンゾカイン、プロカイン、リドカイン、テトラカイン
ホルモン剤
エストロゲン、エストラジオール、テストステロン、プ
ロゲステロン、プロスタグランジン、インスリン
抗凝血剤
ヘパリン
抗生物質
テトラサイクリン、クロラムフェニコール
睡眠薬
フェノバルビタール、アモバルビタールThere are no particular restrictions on the drugs that can be added to the base for this preparation, but the main ones are as follows. Antipyretic and anti-inflammatory analgesic indomethacin, salicylic acid, aspirin, acetaminophenone, diclofenac sodium, ibuprofen steroidal anti-inflammatory drug hydrocortisone, prednisolone, fluocinolone acetonide, hydrocortisone acetate, betamethasone acetate,
Triamcinolone acetonide hypertension, antiarrhythmic agents propranolol, atenolol, pindolol, quinidine sulfate, alprenolol hydrochloride antitumor agent 5-fluorouracil, 1- (2-tetrahydrofuryl) -5-fluorouracil, mitomycin C local anesthetic benzocaine, procaine, Lidocaine, tetracaine hormone estrogen, estradiol, testosterone, progesterone, prostaglandin, insulin anticoagulant heparin antibiotic tetracycline, chloramphenicol hypnotic phenobarbital, amobarbital
【０００７】[0007]
【作用】本発明基剤はＨＰＣ及び／又はＰＶＰ対タンニ
ン物質との比率を適切に変えることにより、その性質を
容易にコントロールすることができる。即ち、両者の比
率を変えることにより、基剤の硬さ、弾力性、溶解性、
粘着性等を自由に変化せしめることができる。詳しく述
べるならば、タンニン物質の比率を高くすると硬さが増
し、粘着性は減少する。逆にタンニン物質の比率を低く
すれば硬さは減少し、粘着性が増加する。更に詳しく述
べれば、本発明基剤の溶解性はタンニン物質の配合比に
よって変化する。タンニン物質の比率が高ければ溶解性
は低下し、比率が低ければ溶解性は高まる。又本基剤の
粘着性は上記の如くタンニン物質の量によって変化する
がＰＶＰの量によっても変化する。即ちＰＶＰの量を多
くすれば粘着性は増加し、少なくすれば粘着性は低下す
る。よって、ＰＶＰとタンニン物質の量を適切に加減す
ることによって、目的とする製剤に合った基剤を得るこ
とができる。このように本発明の製剤用基剤は、ＨＰＣ
とＰＶＰの比率並びにＨＰＣ及び／またはＰＶＰとタン
ニン物質との比率を適切に変化させることにより、その
硬さ、溶解性、粘着性等を自由に変化せしめることがで
きることが特徴である。なお、タンニン物質としては、
タンニン酸が最も好ましい。そして、ＨＰＣとタンニン
酸、ＨＰＣ及びＰＶＰとタンニン酸が好ましい組み合わ
せである。そしてＨＰＣ及び／又はＰＶＰとタンニン物
質の比率はその重量割合で１０００：１〜５：１であ
り、好ましくは５００：１〜１０：１である。The properties of the base material of the present invention can be easily controlled by appropriately changing the ratio of HPC and / or PVP to the tannin substance. That is, by changing the ratio of the two, the hardness, elasticity, solubility of the base,
The adhesiveness etc. can be changed freely. More specifically, increasing the proportion of tannin material increases hardness and decreases tackiness. Conversely, lowering the ratio of tannin substances decreases hardness and increases tackiness. More specifically, the solubility of the base of the present invention varies depending on the compounding ratio of the tannin substance. The higher the ratio of tannin substances, the lower the solubility, and the lower the ratio, the higher the solubility. Further, the tackiness of this base changes depending on the amount of tannin substance as described above, but also changes depending on the amount of PVP. That is, if the amount of PVP is increased, the tackiness increases, and if it is decreased, the tackiness decreases. Therefore, by appropriately adjusting the amounts of PVP and tannin substance, it is possible to obtain a base material suitable for the intended preparation. Thus, the pharmaceutical base of the present invention is
It is characterized in that the hardness, solubility, adhesiveness and the like can be freely changed by appropriately changing the ratio of the PPC and the PVP and the ratio of the HPC and / or the PVP and the tannin substance. As the tannin substance,
Tannic acid is most preferred. And HPC and tannic acid, HPC and PVP and tannic acid are preferable combinations. The weight ratio of HPC and / or PVP to the tannin substance is 1000: 1 to 5: 1, preferably 500: 1 to 10: 1.
【０００８】以下に本発明の製剤用基剤を利用するいく
つかの製剤等の製造方法を説明する。
Ａ．口腔用徐放製剤（フィルムタイプ）の製造法
所定量のＨＰＣ及び／又はＰＶＰ、タンニン物質、薬
剤、必要により可塑剤その他の材料を、それら物質可溶
性の溶媒に溶解し、これを剥離フィルム上に適当量展延
乾燥し、そしてそれを所望の形・大きさに裁断し、そし
て必要により密封包装し、製品とする。
Ｂ．口腔粘膜貼付剤等の支持層の製造法
所定量のＨＰＣ及び／又はＰＶＰ、タンニン物質及び必
要により可塑剤その他の材料を、それら物質可溶性の溶
媒に溶解し、これを剥離フィルム上に適当量展延乾燥
し、支持層とする（剥離フィルムは必要により剥がせば
よい）。なお口腔粘膜貼付剤とするには、この支持層の
上に薬物含有接着層を通常の方法で積層すればよく、こ
の接着層としては上記Ａで述べた製剤を積層することも
できる。
Ｃ．徐放性錠剤の製造法
所定量のＨＰＣ及び／又はＰＶＰ、タンニン物質及び必
要により可塑剤その他の材料を、それら物質可溶性の溶
媒（例えばエタノール）に溶解し、これを所定の型容器
に適当量を流し込み乾燥し、製品とする。
Ｄ．絆創膏の傷口パッドの製造法
所定量のＨＰＣ及び／又はＰＶＰ、タンニン物質及び必
要により可塑剤その他の材料を、それら物質可溶性の溶
媒（例えばエタノール）に溶解し、これを剥離フィルム
上に適当量展延乾燥し、そしてそれを所望の形、大きさ
に裁断、滅菌し、絆創膏の傷口パッドとする。[0008] Hereinafter, some methods for producing a preparation and the like using the base for preparation of the present invention will be described. A. Method for producing sustained-release preparation for oral cavity (film type) A predetermined amount of HPC and / or PVP, a tannin substance, a drug, and optionally a plasticizer and other materials are dissolved in a solvent in which these substances are soluble, and this is dissolved on a release film. The product is spread and dried in an appropriate amount, cut into a desired shape and size, and optionally hermetically packaged to obtain a product. B. Method for manufacturing support layer for oral mucosal patch etc. Predetermined amount of HPC and / or PVP, tannin substance and, if necessary, plasticizer and other materials are dissolved in a solvent in which these substances are soluble, and this is spread on a release film in an appropriate amount. Spread and dry to form a support layer (the release film may be peeled off if necessary). In addition, in order to prepare an oral mucosa patch, a drug-containing adhesive layer may be laminated on this support layer by a usual method, and as the adhesive layer, the preparation described in A above may be laminated. C. Method for producing sustained-release tablet A predetermined amount of HPC and / or PVP, a tannin substance and, if necessary, a plasticizer and other materials are dissolved in a solvent (eg, ethanol) in which those substances are soluble, and an appropriate amount of this is dissolved in a predetermined mold container. Pour and dry to obtain the product. D. Method for manufacturing wound pad of adhesive bandage Predetermined amount of HPC and / or PVP, tannin substance and, if necessary, plasticizer and other materials are dissolved in a solvent (for example, ethanol) soluble in these substances, and this is spread on release film in appropriate amount. It is spread and dried, and it is cut into a desired shape and size and sterilized to obtain a wound pad of a plaster.
【０００９】[0009]
【実施例】以下に本発明を比較例および実施例を挙げて
説明するが、本発明はこれらに限定されるものでないこ
とは言うまでもない。またこれら比較例および実施例に
ついての各剤の組合せおよび含有量については、まとめ
て表１〜３に示している。表中、Ｈはヒドロキシプロピ
ルセルロースを、Ｐはポリビニルピロリドン、Ｔはタン
ニン物質を、Ｓは溶媒を、可は可塑剤を、Ａは薬剤を、
無印はその他の任意成分を示す。
比較例１
エタノールの適量にトリアムシノロンアセトニド（以下
「ＴＡＣＡ」と記す）０．２重量部及びヒドロキシプロ
ピルセルロース（以下「ＨＰＣ」と記す）９９．８重量
部を加えて撹拌溶解し、これをポリエステル剥離フィル
ム上に展延乾燥して厚さ約１８０μｍのフィルムを製造
した。これを直径１２ｍｍの円形状に裁断し、口内炎用
粘膜貼付剤を得た。
比較例２
エタノールの適量にＴＡＣＡ ０．２重量部、ポリビニ
ルピロリドン（以下「ＰＶＰ」と記す）８９．８重量部
及びプロピレングリコール（以下「ＰＧ」と記す）１
０．０重量部を加えて撹拌溶解し、これをポリエステル
剥離フィルム上に展延乾燥して厚さ約１８０μｍのフィ
ルムを製造した。これを直径１２ｍｍの円形状に裁断
し、口内炎用粘膜貼付剤を得た。
実施例１
エタノールの適量にＴＡＣＡ ０．２重量部、タンニン
酸１０．０重量部及びＨＰＣ ８９．８重量部を加えて
撹拌溶解し、これをポリエステル剥離フィルム上に展延
乾燥して厚さ約１８０μｍのフィルムを製造した。これ
を直径１２ｍｍの円形状に裁断し、口内炎用徐放性粘膜
貼付剤を得た。
実施例２
エタノールの適量にＴＡＣＡ ０．２重量部、タンニン
酸１．０重量部及びＨＰＣ ９８．８重量部を加えて撹
拌溶解し、これをポリエステル剥離フィルム上に展延乾
燥して厚さ約１８０μｍのフィルムを製造した。これを
直径１２ｍｍの円形状に裁断し、口内炎用徐放性粘膜貼
付剤を得た。
実施例３
エタノールの適量にＴＡＣＡ ０．２重量部、タンニン
酸０．２重量部及びＨＰＣ ９９．６重量部を加えて撹
拌溶解し、これをポリエステル剥離フィルム上に展延乾
燥して厚さ約１８０μｍのフィルムを製造した。これを
直径１２ｍｍの円形状に裁断し、口内炎用徐放性粘膜貼
付剤を得た。
実施例４
エタノールの適量にイブプロフェン２．０重量部、タン
ニン酸０．５重量部、ＨＰＣ ７０．０重量部、ＰＶＰ
１７．５重量部及びマクロゴール ４００ １０．０重
量部を加えて撹拌溶解し、これをポリエステル剥離フィ
ルム上に展延乾燥して厚さ約１５０μｍのフィルムを製
造した。これを直径１５ｍｍの円形状に裁断し、徐放性
粘膜貼付剤を得た。
実施例５
エタノールの適量に硝酸イソソルビド５．０重量部、タ
ンニン酸１．０重量部、没食子酸１．０重量部、ＨＰＣ
５０．０重量部、ＰＶＰ ３３．０重量部及びマクロゴ
ール ４００ １０．０重量部を加えて撹拌溶解し、こ
れをポリエステル剥離フィルム上に展延乾燥して厚さ約
２００μｍのフィルムを製造した。これを直径１５ｍｍ
の円形状に裁断し、経粘膜吸収型徐放性強心症薬を得
た。
実施例６
エタノールの適量に塩酸プロプラノロール５．０重量
部、タンニン酸１．０重量部、ＨＰＣ ５０．０重量
部、ＰＶＰ ３１．０重量部、カルボキシビニルポリマ
ー３．０重量部及びマクロゴール ４００ １０．０重
量部を加えて撹拌溶解し、これをポリエステル剥離フィ
ルム上に展延乾燥して厚さ約１５０μｍのフィルムを製
造した。これを直径１５ｍｍの円形状に裁断し、徐放性
粘膜貼付剤を得た。
実施例７
エタノールの適量にフマル酸フォルモテロール０．１重
量部、タンニン酸３．０重量部、ＨＰＣ ３０．０重量
部、ＰＶＰ ５１．９重量部、エチルセルロース５．０
重量部及びマクロゴール ４００ １０．０重量部を加
えて撹拌溶解し、これをポリエステル剥離フィルム上に
展延乾燥して厚さ約１５０μｍのフィルムを製造した。
これを直径１２ｍｍの円形状に裁断し、徐放性粘膜貼付
剤を得た。EXAMPLES The present invention will be described below with reference to Comparative Examples and Examples, but it goes without saying that the present invention is not limited to these. Tables 1 to 3 collectively show the combinations and contents of the agents in these Comparative Examples and Examples. In the table, H is hydroxypropylcellulose, P is polyvinylpyrrolidone, T is a tannin substance, S is a solvent, K is a plasticizer, A is a drug,
No mark indicates other optional components. Comparative Example 1 0.2 parts by weight of triamcinolone acetonide (hereinafter referred to as "TACA") and 99.8 parts by weight of hydroxypropyl cellulose (hereinafter referred to as "HPC") were added to an appropriate amount of ethanol, and the mixture was stirred and dissolved to obtain polyester. It was spread and dried on a release film to produce a film having a thickness of about 180 μm. This was cut into a circular shape with a diameter of 12 mm to obtain a mucous membrane patch for stomatitis. Comparative Example 2 TACA 0.2 parts by weight, polyvinylpyrrolidone (hereinafter referred to as "PVP") 89.8 parts by weight, and propylene glycol (hereinafter referred to as "PG") 1 in an appropriate amount of ethanol.
0.0 parts by weight was added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 180 μm. This was cut into a circular shape with a diameter of 12 mm to obtain a mucous membrane patch for stomatitis. Example 1 TACA (0.2 parts by weight), tannic acid (10.0 parts by weight) and HPC (89.8 parts by weight) were added to an appropriate amount of ethanol, and the mixture was stirred and dissolved, and this was spread and dried on a polyester release film to a thickness of about 1. A 180 μm film was produced. This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 2 0.2 parts by weight of TACA, 1.0 part by weight of tannic acid and 98.8 parts by weight of HPC were added to an appropriate amount of ethanol, dissolved by stirring, and spread on a polyester release film to dry to a thickness of about 2. A 180 μm film was produced. This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 3 0.2 parts by weight of TACA, 0.2 parts by weight of tannic acid and 99.6 parts by weight of HPC were added to an appropriate amount of ethanol, dissolved by stirring, and spread to dry on a polyester release film to a thickness of about 3. A 180 μm film was produced. This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 4 2.0 parts by weight of ibuprofen, 0.5 parts by weight of tannic acid, 70.0 parts by weight of HPC, PVP in appropriate amount of ethanol
17.5 parts by weight and 10.0 parts by weight of Macrogol 400 were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 150 μm. This was cut into a circular shape having a diameter of 15 mm to obtain a sustained release mucous membrane patch. Example 5 5.0 parts by weight of isosorbide dinitrate, 1.0 part by weight of tannic acid, 1.0 part by weight of gallic acid, HPC in appropriate amount of ethanol
50.0 parts by weight, 33.0 parts by weight of PVP and 10.0 parts by weight of Macrogol 400 were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 200 μm. This is 15mm in diameter
It was cut into a circular shape to obtain a transmucosal absorption type sustained release cardiotonic drug. Example 6 Propranolol hydrochloride 5.0 parts by weight, tannic acid 1.0 part by weight, HPC 50.0 parts by weight, PVP 31.0 parts by weight, carboxyvinyl polymer 3.0 parts by weight and macrogol 400 10 in appropriate amount of ethanol. 0.0 parts by weight was added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 150 μm. This was cut into a circular shape having a diameter of 15 mm to obtain a sustained release mucous membrane patch. Example 7 Formoterol fumarate 0.1 parts by weight, tannic acid 3.0 parts by weight, HPC 30.0 parts by weight, PVP 51.9 parts by weight, ethyl cellulose 5.0 in appropriate amount of ethanol.
Parts by weight and 10.0 parts by weight of Macrogol 400 were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 150 μm.
This was cut into a circular shape having a diameter of 12 mm to obtain a sustained release mucous membrane patch.
【００１０】[0010]
【表１】 [Table 1]
【００１１】比較例３
エタノールの適量にＨＰＣ ９５．０重量部及びＰＧ
５．０重量部を加えて撹拌溶解し、これをポリエステル
剥離フィルム上に展延乾燥して厚さ約５０μｍのフィル
ムを製造した。別に接着層としてエタノールの適量にＴ
ＡＣＡ ０．２重量部、ＨＰＣ ４０．０重量部、ＰＶＰ
４９．８重量部及びＰＧ １０．０重量部を加えて撹拌
溶解し、支持層フィルム上に展延乾燥して厚さ約１００
μｍの接着層を積層した。これを直径１２ｍｍの円形状
に裁断し、口内炎用粘膜貼付剤を得た。Comparative Example 3 95.0 parts by weight of HPC and PG were added to an appropriate amount of ethanol.
5.0 parts by weight was added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, as an adhesive layer, add an appropriate amount of ethanol to T
ACA 0.2 parts by weight, HPC 40.0 parts by weight, PVP
49.8 parts by weight and 10.0 parts by weight of PG were added, dissolved by stirring, spread on a support layer film and dried to a thickness of about 100.
A μm adhesive layer was laminated. This was cut into a circular shape with a diameter of 12 mm to obtain a mucous membrane patch for stomatitis.
【００１２】実施例８
エタノールの適量にタンニン酸１０．０重量部、ＨＰＣ
８５．０重量部及びＰＧ ５．０重量部を加えて撹拌溶
解し、これをポリエステル剥離フィルム上に展延乾燥し
て厚さ約５０μｍのフィルムを製造した。別に接着層と
してエタノールの適量にＴＡＣＡ ０．２重量部、ＨＰ
Ｃ ４０．０重量部、ＰＶＰ ４９．８重量部及びＰＧ
１０．０重量部を加えて撹拌溶解し、支持層フィルム上
に展延乾燥して厚さ約１００μｍの接着層を積層した。
これを直径１２ｍｍの円形状に裁断し、口内炎用徐放性
粘膜貼付剤を得た。
実施例９
エタノールの適量にタンニン酸３．０重量部、ＨＰＣ
９２．０重量部及びＰＧ ５．０重量部を加えて撹拌溶
解し、これをポリエステル剥離フィルム上に展延乾燥し
て厚さ約５０μｍのフィルムを製造した。別に接着層と
してエタノールの適量にＴＡＣＡ ０．２重量部、ＨＰ
Ｃ ４０．０重量部、ＰＶＰ ４９．８重量部及びＰＧ
１０．０重量部を加えて撹拌溶解し、支持層フィルム上
に展延乾燥して厚さ約１００μｍの接着層を積層した。
これを直径１２ｍｍの円形状に裁断し、口内炎用徐放性
粘膜貼付剤を得た。
実施例１０
エタノールの適量にタンニン酸０．５重量部、ＨＰＣ
９４．５重量部及びＰＧ ５．０重量部を加えて撹拌溶
解し、これをポリエステル剥離フィルム上に展延乾燥し
て厚さ約５０μｍのフィルムを製造した。別に接着層と
してエタノールの適量にＴＡＣＡ ０．２重量部、ＨＰ
Ｃ ４０．０重量部、ＰＶＰ ４９．８重量部及びＰＧ
１０．０重量部を加えて撹拌溶解し、支持層フィルム上
に展延乾燥して厚さ約１００μｍの接着層を積層した。
これを直径１２ｍｍの円形状に裁断し、口内炎用徐放性
粘膜貼付剤を得た。
実施例１１
エタノールの適量にタンニン酸３．０重量部、ＨＰＣ
６７．０重量部、エチルセルロース２０．０重量部及び
マクロゴール ４００ １０．０重量部を加えて撹拌溶
解し、これをポリエステル剥離フィルム上に展延乾燥し
て厚さ約５０μｍのフィルムを製造した。別に接着層と
してエタノールの適量に硝酸イソソルビド５．０重量
部、ＨＰＣ ４０．０重量部、ＰＶＰ ４５．０重量部及
びマクロゴール ４００ １０．０重量部を加えて撹拌
溶解し、支持層フィルム上に展延乾燥して厚さ約１００
μｍの接着層を積層した。これを直径１５ｍｍの円形状
に裁断し、経粘膜吸収型徐放性強心症薬を得た。
実施例１２
エタノールの適量にタンニン酸５．０重量部、ＨＰＣ
８５．０重量部及びＰＧ １０．０重量部を加えて撹拌
溶解し、これをポリエステル剥離フィルム上に展延乾燥
して厚さ約５０μｍのフィルムを製造した。別に接着層
としてエタノールの適量に塩酸プロプラノロール５．０
重量部、ＨＰＣ ５０．０重量部、ＰＶＰ ３５．０重量
部及びＰＧ １０．０重量部を加えて撹拌溶解し、支持
層フィルム上に展延乾燥して厚さ約１００μｍの接着層
を積層した。これを直径１５ｍｍの円形状に裁断し、徐
放性粘膜貼付剤を得た。
実施例１３
エタノールの適量にタンニン酸１０．０重量部、ＨＰＣ
８０．０重量部及びマクロゴール ４００ １０．０重
量部を加えて撹拌溶解し、これをポリエステル剥離フィ
ルム上に展延乾燥して厚さ約５０μｍのフィルムを製造
した。別に接着層としてエタノールの適量にフマル酸フ
ォルモテロール０．１重量部、ＨＰＣ ７９．９重量
部、カルボキシビニルポリマー１０．０重量部及びマク
ロゴール ４００ １０．０重量部を加えて撹拌溶解
し、支持層フィルム上に展延乾燥して厚さ約１００μｍ
の接着層を積層した。これを直径１５ｍｍの円形状に裁
断し、徐放性粘膜貼付剤を得た。Example 8 10.0 parts by weight of tannic acid, HPC in appropriate amount of ethanol
85.0 parts by weight and 5.0 parts by weight of PG were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, as an adhesive layer, TACA 0.2 parts by weight, HP
C 40.0 parts by weight, PVP 49.8 parts by weight and PG
10.0 parts by weight was added, and the mixture was stirred and dissolved, spread and dried on the support layer film, and an adhesive layer having a thickness of about 100 μm was laminated.
This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 9 3.0 parts by weight of tannic acid, HPC in appropriate amount of ethanol
92.0 parts by weight and 5.0 parts by weight of PG were added, stirred and dissolved, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, as an adhesive layer, TACA 0.2 parts by weight, HP
C 40.0 parts by weight, PVP 49.8 parts by weight and PG
10.0 parts by weight was added, and the mixture was stirred and dissolved, spread and dried on the support layer film, and an adhesive layer having a thickness of about 100 μm was laminated.
This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 10 0.5 part by weight of tannic acid in a proper amount of ethanol, HPC
94.5 parts by weight and 5.0 parts by weight of PG were added, stirred and dissolved, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, as an adhesive layer, TACA 0.2 parts by weight, HP
C 40.0 parts by weight, PVP 49.8 parts by weight and PG
10.0 parts by weight was added, and the mixture was stirred and dissolved, spread and dried on the support layer film, and an adhesive layer having a thickness of about 100 μm was laminated.
This was cut into a circular shape having a diameter of 12 mm to obtain a sustained-release mucous membrane patch for stomatitis. Example 11 3.0 parts by weight of tannic acid and HPC in an appropriate amount of ethanol
67.0 parts by weight, ethyl cellulose 20.0 parts by weight and Macrogol 400 10.0 parts by weight were added, stirred and dissolved, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, 5.0 parts by weight of isosorbide dinitrate, 40.0 parts by weight of HPC, 45.0 parts by weight of PVP and 10.0 parts by weight of Macrogol 400 were added to an appropriate amount of ethanol as an adhesive layer, and dissolved by stirring to form a film on the support layer film. Spread and dry to a thickness of about 100
A μm adhesive layer was laminated. This was cut into a circular shape with a diameter of 15 mm to obtain a transmucosal absorption type sustained release cardiotonic drug. Example 12 An appropriate amount of ethanol, 5.0 parts by weight of tannic acid, HPC
85.0 parts by weight and 10.0 parts by weight of PG were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, propranolol hydrochloride 5.0 was added to the appropriate amount of ethanol as an adhesive layer.
Parts by weight, 50.0 parts by weight of HPC, 35.0 parts by weight of PVP and 10.0 parts by weight of PG were added and dissolved by stirring, and spread and dried on a support layer film to laminate an adhesive layer having a thickness of about 100 μm. . This was cut into a circular shape having a diameter of 15 mm to obtain a sustained release mucous membrane patch. Example 13 10.0 parts by weight of tannic acid, HPC in appropriate amount of ethanol
80.0 parts by weight and 10.0 parts by weight of Macrogol 400 were added, stirred and dissolved, and this was spread and dried on a polyester release film to produce a film having a thickness of about 50 μm. Separately, as an adhesive layer, formoterol fumarate (0.1 parts by weight), HPC (79.9 parts by weight), carboxyvinyl polymer (10.0 parts by weight) and Macrogol 400 (10.0 parts by weight) were added to an appropriate amount of ethanol, and the mixture was stirred, dissolved and supported. Approximately 100μm thickness after being spread and dried on the layer film
Adhesive layers were laminated. This was cut into a circular shape having a diameter of 15 mm to obtain a sustained release mucous membrane patch.
【００１３】[0013]
【表２】 [Table 2]
【００１４】実施例１４
エタノールの適量にタンニン酸１０．０重量部及びＨＰ
Ｃ ５０．０重量部、ＰＶＰ ４０．０重量部を加えて撹
拌溶解し、これをポリエステル剥離フィルム上に展延乾
燥して厚さ約３００μｍのシートを製造した。このシー
トを１２ｍｍ×２４ｍｍに裁断し、絆創膏用傷口パット
を得た。別に支持体として約５０μｍのポリ塩化ビニル
フィルム上にメタアクリル酸アクリル酸ブチルコポリマ
ーを展延乾燥して厚さ約１００μｍの粘着テープを製造
した。この粘着テープを２０ｍｍ×７０ｍｍに裁断し、
傷口パットを粘着面に置き、滅菌し、絆創膏とする。
実施例１５
エタノールの適量にアクリノール１．０重量部、タンニ
ン酸５．０重量部及びＨＰＣ ９４．０重量部を加えて
均一分散し、これをポリエステル剥離フィルム上に展延
乾燥して厚さ約３００μｍのシートを製造した。このシ
ートを１２ｍｍ×２４ｍｍに裁断し、絆創膏用傷口パッ
トを得た。別に支持体として約５０μｍのポリ塩化ビニ
ルフィルム上にメタアクリル酸アクリル酸ブチルコポリ
マーを展延乾燥して厚さ約１００μｍの粘着テープを製
造した。この粘着テープを２０ｍｍ×７０ｍｍに裁断
し、傷口パットを粘着面に置き、滅菌し、絆創膏とす
る。
実施例１６
エタノールの適量に硫酸フラジオマイシン０．２重量
部、タンニン酸１０．０重量部、ＨＰＣ ８４．８重量
部及びＰＧ ５．０重量部を加えて均一分散し、これを
ポリエステルフィルム上に展延乾燥して厚さ約５００μ
ｍのフィルムを製造した。これを１００ｍｍ×１００ｍ
ｍに裁断滅菌し、熱傷用外用貼付剤を得た。
実施例１７
エタノールの適量にポビドンヨード３．０重量部、タン
ニン酸１０．０重量部、ＨＰＣ６７．０重量部及びＰＶ
Ｐ ２０．０重量部を加えて撹拌溶解し、これをポリエ
ステルフィルム上に展延乾燥して厚さ約５００μｍのフ
ィルムを製造した。これを１００ｍｍ×１００ｍｍに裁
断滅菌し、褥瘡用外用貼付剤を得た。Example 14 10.0 parts by weight of tannic acid and HP in appropriate amount of ethanol
50.0 parts by weight of C and 40.0 parts by weight of PVP were added and dissolved by stirring, and this was spread and dried on a polyester release film to produce a sheet having a thickness of about 300 μm. This sheet was cut into 12 mm x 24 mm to obtain a wound pad for a plaster. Separately, a butyl methacrylic acid acrylate copolymer was spread and dried on a polyvinyl chloride film having a thickness of about 50 μm as a support to manufacture an adhesive tape having a thickness of about 100 μm. Cut this adhesive tape into 20 mm x 70 mm,
Place the wound pad on the adhesive surface and sterilize to make a bandage. Example 15 To a suitable amount of ethanol, 1.0 part by weight of acrinol, 5.0 parts by weight of tannic acid and 94.0 parts by weight of HPC were added and uniformly dispersed, and this was spread and dried on a polyester release film to a thickness of about. A 300 μm sheet was produced. This sheet was cut into 12 mm x 24 mm to obtain a wound pad for a plaster. Separately, a butyl methacrylic acid acrylate copolymer was spread and dried on a polyvinyl chloride film having a thickness of about 50 μm as a support to manufacture an adhesive tape having a thickness of about 100 μm. This adhesive tape is cut into 20 mm × 70 mm, the wound pad is placed on the adhesive surface and sterilized to obtain a bandage. Example 16 To a suitable amount of ethanol, 0.2 parts by weight of fradiomycin sulfate, 10.0 parts by weight of tannic acid, 84.8 parts by weight of HPC and 5.0 parts by weight of PG were added and uniformly dispersed. Spread and dry to a thickness of about 500μ
m film was produced. This is 100mm × 100m
m was sterilized by cutting to obtain an external patch for burns. Example 17 3.0 parts by weight of povidone iodine, 10.0 parts by weight of tannic acid, 67.0 parts by weight of HPC and PV in appropriate amounts of ethanol
20.0 parts by weight of P was added and dissolved by stirring, and this was spread and dried on a polyester film to produce a film having a thickness of about 500 μm. This was cut and sterilized into 100 mm × 100 mm to obtain an external patch for pressure ulcer.
【００１５】[0015]
【表３】 [Table 3]
【００１６】図１に実施例１〜３及び比較例１で得られ
た貼付剤についての主薬溶出試験結果を示す。実施例１
〜３のものは比較例１のものに比べその主薬の徐放性に
おいて優れていることが分る。FIG. 1 shows the results of the main drug dissolution test of the patches obtained in Examples 1 to 3 and Comparative Example 1. Example 1
It can be seen that those of Nos. 3 to 3 are superior to those of Comparative Example 1 in the sustained release property of the main drug.
【００１７】[0017]
【発明の効果】本発明で得られる製剤用基剤は、その主
薬の徐放性およびそのコントロールに優れ、そのまま或
いは可塑剤を配合して口腔内粘膜貼付剤の支持層として
好適に使用できるとともに、坐剤の基剤、絆創膏のガー
ゼの代替品、化膿性疾患用貼付剤の皮膚接触面部材等と
しても使用することができる。更には調製時、薬剤や可
塑剤を配合することにより非常に良好な各種の徐放性製
剤（例えばトローチ、バツカル、口腔内粘膜貼付剤等の
口腔用の徐放性製剤や一般的徐放性錠剤等）を得ること
ができる。EFFECTS OF THE INVENTION The pharmaceutical base obtained in the present invention is excellent in sustained release of the main drug and its control, and can be suitably used as it is or as a support layer of an intraoral mucosal patch while incorporating a plasticizer. It can also be used as a base for suppositories, a substitute for gauze for plasters, a skin contact surface member for patches for purulent diseases, and the like. Furthermore, during preparation, it is possible to add various drugs and plasticizers at the time of preparation, and various very good sustained release preparations (eg lozenges, buccal, oral mucosal patches, etc. Tablets etc.) can be obtained.
【図１】本発明の実施例１〜３及び比較例１で得られた
貼付剤についての主薬溶出試験結果を示す。FIG. 1 shows the results of a main drug dissolution test for the patches obtained in Examples 1 to 3 of the present invention and Comparative Example 1.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ Ａ６１Ｋ 47/32 Ａ６１Ｋ 47/32 Ａ６１Ｌ 15/58 Ａ６１Ｌ 15/06 (56)参考文献 特開 昭62−22713（ＪＰ，Ａ) 米国特許3777016（ＵＳ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 47/38 A61K 9/00 A61K 9/22 A61K 9/70 A61K 47/26 A61K 47/32 A61L 15/58 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 7 Identification code FI A61K 47/32 A61K 47/32 A61L 15/58 A61L 15/06 (56) Reference JP-A-62-22713 (JP, A) US Patent 3777016 (US, A) (58) Fields investigated (Int.Cl. 7 , DB name) A61K 47/38 A61K 9/00 A61K 9/22 A61K 9/70 A61K 47/26 A61K 47/32 A61L 15 / 58
Claims (7)
はヒドロキシプロピルセルロースとポリビニルピロリド
ンとの混合物、及び（２）タンニン物質を、これら物質
可溶性の溶媒に溶解した後、得られる溶液から溶媒を除
去することによって得られるフィルムからなる製剤用基
剤。1. (1) Hydroxypropyl cellulose, or
Is hydroxypropyl cellulose and polyvinylpyrrolid
Mixture of emissions, and (2) a tannin substance, it was dissolved in a solvent of a substance soluble, pharmaceutical base material comprising a film obtained by removing the solvent from the resulting solution.
子酸である請求項１記載の製剤用基剤。2. The pharmaceutical base according to claim 1, wherein the tannin substance is tannic acid and / or gallic acid.
酸とを組合せて用いる請求項１記載の製剤用基剤。3. The pharmaceutical base according to claim 1, wherein hydroxypropyl cellulose and tannic acid are used in combination.
ニルピロリドンとタンニン酸とを組合せて用いる請求項
１記載の製剤用基剤。4. The base for pharmaceutical preparation according to claim 1, wherein hydroxypropylcellulose and polyvinylpyrrolidone are used in combination with tannic acid.
はヒドロキシプロピルセルロースとポリビニルピロリド
ンとの混合物対（２）タンニン物質の比が重量割合で１
０００：１〜５：１である請求項１記載の製剤用基剤。5. (1) Hydroxypropyl cellulose, or
Is hydroxypropyl cellulose and polyvinylpyrrolid
The ratio of the mixture with benzene to the (2) tannin substance is 1 by weight.
The formulation base according to claim 1, which is 000: 1 to 5: 1.
用基剤。6. The pharmaceutical base according to claim 1, which contains a plasticizer.
製剤用基剤。7. The base material for a pharmaceutical preparation according to claim 1, which further comprises an adhesive layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33288293A JP3496727B2 (en) | 1993-12-27 | 1993-12-27 | Pharmaceutical base |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33288293A JP3496727B2 (en) | 1993-12-27 | 1993-12-27 | Pharmaceutical base |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07187993A JPH07187993A (en) | 1995-07-25 |
| JP3496727B2 true JP3496727B2 (en) | 2004-02-16 |
Family
ID=18259857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33288293A Expired - Fee Related JP3496727B2 (en) | 1993-12-27 | 1993-12-27 | Pharmaceutical base |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3496727B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2371354A1 (en) | 2010-03-30 | 2011-10-05 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
| EP2371358A1 (en) | 2010-03-30 | 2011-10-05 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
| EP2990030A1 (en) | 2014-08-27 | 2016-03-02 | Nitto Denko Corporation | Oral film-form base and preparation |
| US9289386B2 (en) | 2009-01-29 | 2016-03-22 | Nitto Denko Corporation | Oral film-form base and oral film-form preparation |
| US10092505B2 (en) | 2012-01-11 | 2018-10-09 | Nitto Denko Corporation | Oral film-form base and preparation |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8578498A (en) * | 1997-07-23 | 1999-02-16 | Perio Products Ltd. | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
| DE19954421A1 (en) * | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Film-like preparation for the biphase release of pharmacologically active or other substances |
| KR100996044B1 (en) | 2005-08-25 | 2010-11-22 | 더 프록터 앤드 갬블 캄파니 | Absorbent article comprising condensed tannin |
| WO2014038593A2 (en) * | 2012-09-05 | 2014-03-13 | テイカ製薬株式会社 | Granulated material for tablet that rapidly disintegrates in mouth |
| JP6842381B2 (en) * | 2017-08-09 | 2021-03-17 | 救急薬品工業株式会社 | Oral mucosa patch |
-
1993
- 1993-12-27 JP JP33288293A patent/JP3496727B2/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9289386B2 (en) | 2009-01-29 | 2016-03-22 | Nitto Denko Corporation | Oral film-form base and oral film-form preparation |
| EP2371354A1 (en) | 2010-03-30 | 2011-10-05 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
| EP2371358A1 (en) | 2010-03-30 | 2011-10-05 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
| US9724309B2 (en) | 2010-03-30 | 2017-08-08 | Nitto Denko Corporation | Film-form preparation and method for producing the same |
| US10092505B2 (en) | 2012-01-11 | 2018-10-09 | Nitto Denko Corporation | Oral film-form base and preparation |
| EP2990030A1 (en) | 2014-08-27 | 2016-03-02 | Nitto Denko Corporation | Oral film-form base and preparation |
| KR20160025468A (en) | 2014-08-27 | 2016-03-08 | 닛토덴코 가부시키가이샤 | Oral film-form base and preparation |
| US9439872B2 (en) | 2014-08-27 | 2016-09-13 | Nitto Denko Corporation | Oral film-form base and preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07187993A (en) | 1995-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4619894B2 (en) | Drug carrier device suitable for delivery of drug compounds to mucosal surfaces | |
| FI107708B (en) | Process for preparing a matrix for use in a drug delivery device | |
| AU709286B2 (en) | Transdermal estradiol/progestogen agent patch and its production | |
| US5900247A (en) | Mucoadhesive pharmaceutical composition for the controlled release of active principles | |
| KR100343877B1 (en) | Transdermal therapeutic system containing estradiol | |
| JP2656338B2 (en) | Oral mucosa patch preparation | |
| JP2960832B2 (en) | Estradiol administration system | |
| JPS63160649A (en) | Base material adhered to oral cavity | |
| EP0782861A1 (en) | Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation | |
| KR20040039290A (en) | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds | |
| JP2007211030A (en) | Pharmaceutical gel preparation applicable to mucosal surface and body tissue | |
| JPH03502925A (en) | Skin-permeable estradiol delivery system | |
| JP3496727B2 (en) | Pharmaceutical base | |
| JPH02202813A (en) | Percutaneous absorbing preparation | |
| JPH03275619A (en) | External agent composition | |
| JPH10109945A (en) | Plasticizing agent and cataplasm containing the same | |
| JP3193161B2 (en) | Transdermal absorption preparation | |
| JPH0753671B2 (en) | Transdermal / transmucosal preparation | |
| JPS6193112A (en) | Plaster | |
| JPH0533929B2 (en) | ||
| EP1888025B1 (en) | Medicament carrier composition and method of forming a film therefrom | |
| JP3132838B2 (en) | Formulation for oral mucosa | |
| JP3472359B2 (en) | Patch containing timiperone | |
| JP3197035B2 (en) | Formulation for oral mucosa | |
| JPH02250826A (en) | Bandage for oral application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20030610 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20031112 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121128 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |